Save for clinic
📖 Full analysis: Desktop version — complete efficacy tables, safety detail, subgroup data, and clinical implications
🎯 Clinical Bottom Line
Trastuzumab deruxtecan nearly doubled progression-free survival and significantly extended overall survival compared with physician's choice chemotherapy in pretreated HER2-low metastatic breast cancer. This trial created "HER2-low" as a therapeutically actionable category and established T-DXd as the first HER2-directed therapy to benefit this population — roughly half of all metastatic breast cancers previously considered HER2-negative.
Key Result: PFS (HR-positive cohort) — 10.1 vs 5.4 months, HR 0.51 (95% CI 0.40–0.64; P<0.001)
Safety Signal: Drug-related ILD/pneumonitis in 12.1% of T-DXd patients including 3 fatal cases (0.8%). Requires proactive pulmonary monitoring.
✅ Patient Eligibility
Must Have:
- HER2-low: IHC 1+ or IHC 2+/ISH-negative (central testing)
- Unresectable or metastatic breast cancer
- 1–2 prior chemotherapy lines for metastatic disease (or recurrence ≤6 months from adjuvant chemo)
- If HR-positive: ≥1 prior endocrine therapy
Cannot Have:
- History of noninfectious ILD treated with glucocorticoids
- Suspected ILD on screening imaging
- Untreated/unstable brain metastases
💊 Dosing Quick Guide
Experimental Regimen
Trastuzumab deruxtecan: 5.4 mg/kg IV every 3 weeks Duration: Until progression or unacceptable toxicity Median duration on study: 8.2 months
Control Regimen
Physician's choice: Eribulin (51.1%), capecitabine (20.1%), nab-paclitaxel (10.3%), gemcitabine (10.3%), or paclitaxel (8.2%)
Key Dose Modifications [2]
Per FDA prescribing information - Dose reduction levels: 5.4 → 4.4 → 3.2 mg/kg; discontinue if further reduction needed - ILD/pneumonitis: Hold immediately at any grade; permanently discontinue for grade ≥2 - Monitoring: LVEF at baseline and regular intervals; CT imaging at baseline; counsel patients on respiratory symptoms
Mechanism: Trastuzumab deruxtecan is an antibody-drug conjugate linking a HER2-targeted antibody to a topoisomerase I inhibitor payload with a bystander killing effect on neighboring cells [2].
⚠️ Safety Snapshot
| Grade ≥3 Toxicities | T-DXd (n=371) | PC (n=172) |
|---|---|---|
| Neutropenia | 51 (13.7%) | 70 (40.7%) |
| Anemia | 30 (8.1%) | 8 (4.7%) |
| Fatigue | 28 (7.5%) | 8 (4.7%) |
| Leukopenia | 24 (6.5%) | 33 (19.2%) |
| Thrombocytopenia | 19 (5.1%) | 1 (0.6%) |
| Nausea | 17 (4.6%) | 0 |
⚠️ ILD/Pneumonitis: Any grade 45 (12.1%) — Grade 1: 13 (3.5%), Grade 2: 24 (6.5%), Grade 3: 5 (1.3%), Fatal: 3 (0.8%). Median onset: 129 days (range 26–710).
Key safety metrics:
- Treatment-related deaths: T-DXd: see below; PC: 0
- Discontinuations due to AE: 16.2% vs 8.1%
- Dose reductions: 22.6% vs 38.4%
- Serious AEs: 27.8% vs 25.0%
- Fatal AEs: 14 (3.8%) vs 5 (2.9%)
Drug-related deaths in T-DXd arm: pneumonitis (2), ischemic colitis, DIC, dyspnea, febrile neutropenia, sepsis (1 each). No drug-related deaths with physician's choice.
📊 Key Numbers
Median follow-up: 18.4 months
| Outcome (Population) | T-DXd | PC | HR (95% CI) | p-value |
|---|---|---|---|---|
| PFS, HR+ cohort | 10.1 mo | 5.4 mo | 0.51 (0.40–0.64) | P<0.001 |
| PFS, all patients | 9.9 mo | 5.1 mo | 0.50 (0.40–0.63) | P<0.001 |
| OS, HR+ cohort | 23.9 mo | 17.5 mo | 0.64 (0.48–0.86) | P=0.003 |
| OS, all patients | 23.4 mo | 16.8 mo | 0.64 (0.49–0.84) | P=0.001 |
| ORR, HR+ cohort | 52.6% | 16.3% | — | — |
| ORR, all patients | 52.3% | 16.3% | — | — |
| PFS, HR− cohort* | 8.5 mo | 2.9 mo | 0.46 (0.24–0.89) | — |
| OS, HR− cohort* | 18.2 mo | 8.3 mo | 0.48 (0.24–0.95) | — |
Exploratory; small sample (n=63), not formally tested
OS analysis was an interim analysis — P values crossed the prespecified stopping boundary of 0.0075.
🔬 Key Comparator Context
| Trial | Regimen | Population | Primary Endpoint | Key Result | Ref |
|---|---|---|---|---|---|
| DESTINY-Breast04 | T-DXd vs PC | HER2-low mBC, 1–2 prior chemo | PFS (HR+ cohort) | 10.1 vs 5.4 mo; HR 0.51 | [1] |
| DESTINY-Breast06 | T-DXd vs PC | HER2-low/ultralow HR+ mBC, post-ET | PFS | See [4] | [4] |
| TROPiCS-02 | SG vs PC | HR+/HER2− mBC, 2–4 prior chemo | PFS | See [5] | [5] |
Cross-trial comparisons are limited by differences in populations, designs, and endpoints.
🔍 Subgroups to Watch
HER2 IHC 1+ (T-DXd arm): Median PFS 10.3 months — benefit not limited to higher HER2-low expression HER2 IHC 2+/ISH-neg (T-DXd arm): Median PFS 10.1 months — consistent across HER2-low categories Prior CDK4/6i (T-DXd arm): Median PFS 10.0 months — active in post-CDK4/6i setting No prior CDK4/6i (T-DXd arm): Median PFS 11.7 months
Subgroup analyses were not powered for formal comparisons. Results are hypothesis-generating.
📋 Regulatory Status
| Region | Status |
|---|---|
| FDA | Approved (Aug 2022) for HER2-low mBC after prior chemo; subsequently broadened to HER2-ultralow [2] |
| EMA | Approved for similar indications |
⚠️ Verify current regulatory status before prescribing.
NCCN: Preferred regimen for HER2-low metastatic breast cancer (Category 1) [3]
⚡ Grey Zones
- HER2-zero excluded — boundary of HER2 expression for T-DXd activity remains undefined; IHC 0 vs 1+ scoring is poorly reproducible
- ADC sequencing unknown — no randomized data on T-DXd vs sacituzumab govitecan order or cross-resistance
- Brain metastases underrepresented — only ~5–6% had baseline CNS disease; intracranial activity in HER2-low unclear
- Open-label design — may bias subjective AE reporting and investigator-assessed outcomes (primary used BICR)
- Late ILD risk uncertain — onset up to 710 days; cumulative risk with prolonged therapy unknown
📖 Full Analysis
Read the complete desktop article with full efficacy tables, safety detail, subgroup data, comparator trials, and clinical implications at kill-cancer.com
About the Author
Andrew Stevenson is the founder and systems architect of kill-cancer.com. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces to its source publication. Zero calculation. Zero editorializing. Zero hallucination. Five siblings lost to cancer built the urgency. The engineering builds the trust.
📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum
For healthcare professionals only. Not medical advice. Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability. Consult FDA labeling, NCCN guidelines, and institutional protocols.
References
- Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9-20. doi:10.1056/NEJMoa2203690
- Enhertu (trastuzumab deruxtecan) prescribing information. U.S. Food and Drug Administration. Accessed March 2026.
- NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2026. Accessed March 2026.
- Curigliano G, Hu X, Dent RA, et al. Trastuzumab deruxtecan vs physician's choice treatment in patients with HER2-low or HER2-ultralow hormone receptor–positive metastatic breast cancer: DESTINY-Breast06. JAMA. 2024. doi:10.1001/jama.2024.18268
- Rugo HS, Bardia A, Marmé F, et al. Sacituzumab govitecan in hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic breast cancer (TROPiCS-02). J Clin Oncol. 2023;41(21):3709-3720. doi:10.1200/JCO.22.01966